Solos Endoscopy Inc (SNDY) 0.0011 $SNDY
Health Canada's Medical Device Bureau Completes Evaluation of Solos Endoscopic Instruments for Canada
eTeligis - Wed Apr 30, 8:03AM CDT
Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS:SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that Health Canada's Medical Device Bureau (MDB) has completed its initial evaluation of certain Solos Endoscopy instruments and has classified its devices as Class II medical devices.
Solos Endoscopy Reports Financial Results for Period Ended December 31, 2013
Marketwire - Tue Apr 01, 9:05AM CDT
Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, reported sales and earnings results for the period ended December 31, 2013.
Solos Endoscopy to Begin Distribution of Its Endoscopic Instruments in Canada
Marketwire - Thu Feb 20, 10:41AM CST
Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView(R) devices in Canada.
Halozyme Announces Positive Opinion From CHMP For European Approval Of Roche's MabThera SC
PR Newswire - Fri Jan 24, 10:32AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera® (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL).
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire - Thu Jan 16, 1:00PM CST
Dublin - Research and Markets (http://www.researchandmarkets.com/research/sqmftt/pain_therapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Solos Endoscopy Completes Stage 2 of its ISO 13485 Audit with TUV SUD America
ACCESSWIRE - Thu Aug 22, 8:06AM CDT
BOSTON, MA, August 22, 2013 - (Accesswire) - Solos Endoscopy, Inc. (OTCPink: SNDY) is pleased to announce that TUV SUD America has completed its Stage 2 ISO 13485 Audit with Solos Endoscopy on August 16, 2013. Solos Endoscopy will be certified to ISO 13485:2003, the internationally-recognized standard for quality systems for medical device manufacturers, once it reviews and resolves any corrective actions that were discovered during the final audit.
Solos Endoscopy Reports 2nd Quarter Results
ACCESSWIRE - Wed Aug 14, 11:15AM CDT
Company Posts Financials for Period Ended June 30, 2013, President's Letter to Shareholders
Solos Endoscopy Retains Emergo Group to be the Authorized Representative for the Importation of Solos Instruments into Europe
ACCESSWIRE - Fri Aug 02, 8:06AM CDT
BOSTON, August 2, 2013 - Solos Endoscopy, Inc. (OTC PINK: SNDY) is pleased to announce that the Company has retained Emergo Group to act as the Company's authorized representative in Europe. Emergo Group will provide Solos assistance related to communications with authorities and importation of Solos instruments into Europe.
Solos Endoscopy's MammoView(R) System Offers Women Early Breast Cancer Detection
ACCESSWIRE - Thu Jul 18, 12:01PM CDT
BOSTON, MA, July 18, 2013 - (eTeligis via ACCESSWIRE) - Solos Endoscopy, Inc. (OTC PINK: SNDY) is pleased to announce that the Company's MammoView(R) Breast Endoscopy System can aid in giving women the best prognosis for recovery by detecting breast cancer at an earlier stage than conventional methods (http://www.solosendoscopy.com/ductoscope-sell-sheet-final.pdf).
Solos Endoscopy and TUV SUD America Schedule Stage 2 ISO 13485 Audit for August 16, 2013
PR Newswire - Wed Jun 12, 9:06AM CDT
Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy Reports Full Year 2012 Results
PR Newswire - Wed May 15, 8:36AM CDT
Solos Endoscopy, Inc. (OTCPK: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, reported sales and earnings results for the full year ended December 31, 2012.
Solos Endoscopy Management Announces Goals for 2013
PR Newswire - Fri Jan 04, 9:16AM CST
Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company plans to continue its progress in 2013 as its management has announced its goals for moving forward in the New Year.
Health Canada's Medical Device Bureau Completes Evaluation of Solos Endoscopic Instruments for Canada
eTeligis - Wed Apr 30, 8:03AM CDT
Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS:SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that Health Canada's Medical Device Bureau (MDB) has completed its initial evaluation of certain Solos Endoscopy instruments and has classified its devices as Class II medical devices.
Solos Endoscopy Reports Financial Results for Period Ended December 31, 2013
Marketwire - Tue Apr 01, 9:05AM CDT
Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, reported sales and earnings results for the period ended December 31, 2013.
Solos Endoscopy to Begin Distribution of Its Endoscopic Instruments in Canada
Marketwire - Thu Feb 20, 10:41AM CST
Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView(R) devices in Canada.
Halozyme Announces Positive Opinion From CHMP For European Approval Of Roche's MabThera SC
PR Newswire - Fri Jan 24, 10:32AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera® (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL).
Pain Therapeutics - Drugs, Markets and Companies
PR Newswire - Thu Jan 16, 1:00PM CST
Dublin - Research and Markets (http://www.researchandmarkets.com/research/sqmftt/pain_therapeutics) has announced the addition of a new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Solos Endoscopy Completes Stage 2 of its ISO 13485 Audit with TUV SUD America
ACCESSWIRE - Thu Aug 22, 8:06AM CDT
BOSTON, MA, August 22, 2013 - (Accesswire) - Solos Endoscopy, Inc. (OTCPink: SNDY) is pleased to announce that TUV SUD America has completed its Stage 2 ISO 13485 Audit with Solos Endoscopy on August 16, 2013. Solos Endoscopy will be certified to ISO 13485:2003, the internationally-recognized standard for quality systems for medical device manufacturers, once it reviews and resolves any corrective actions that were discovered during the final audit.
Solos Endoscopy Reports 2nd Quarter Results
ACCESSWIRE - Wed Aug 14, 11:15AM CDT
Company Posts Financials for Period Ended June 30, 2013, President's Letter to Shareholders
Solos Endoscopy Retains Emergo Group to be the Authorized Representative for the Importation of Solos Instruments into Europe
ACCESSWIRE - Fri Aug 02, 8:06AM CDT
BOSTON, August 2, 2013 - Solos Endoscopy, Inc. (OTC PINK: SNDY) is pleased to announce that the Company has retained Emergo Group to act as the Company's authorized representative in Europe. Emergo Group will provide Solos assistance related to communications with authorities and importation of Solos instruments into Europe.
Solos Endoscopy's MammoView(R) System Offers Women Early Breast Cancer Detection
ACCESSWIRE - Thu Jul 18, 12:01PM CDT
BOSTON, MA, July 18, 2013 - (eTeligis via ACCESSWIRE) - Solos Endoscopy, Inc. (OTC PINK: SNDY) is pleased to announce that the Company's MammoView(R) Breast Endoscopy System can aid in giving women the best prognosis for recovery by detecting breast cancer at an earlier stage than conventional methods (http://www.solosendoscopy.com/ductoscope-sell-sheet-final.pdf).
Solos Endoscopy and TUV SUD America Schedule Stage 2 ISO 13485 Audit for August 16, 2013
PR Newswire - Wed Jun 12, 9:06AM CDT
Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy Reports Full Year 2012 Results
PR Newswire - Wed May 15, 8:36AM CDT
Solos Endoscopy, Inc. (OTCPK: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, reported sales and earnings results for the full year ended December 31, 2012.
Solos Endoscopy Management Announces Goals for 2013
PR Newswire - Fri Jan 04, 9:16AM CST
Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company plans to continue its progress in 2013 as its management has announced its goals for moving forward in the New Year.
